Foghorn Therapeutics Inc.

16.65+0.6550+4.10%Vol 111.86K1Y Perf 85.77%
Aug 5th, 2022 16:00 DELAYED
BID12.60 ASK20.12
Open15.56 Previous Close16.00
Pre-Market- After-Market16.65
 - -  - -%
Target Price
24.00 
Analyst Rating
Strong Buy 1.10
Potential %
44.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     41.21
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
52.91 
Earnings Rating
Market Cap690.43M 
Earnings Date
9th Aug 2022
Alpha0.01 Standard Deviation0.32
Beta2.47 

Today's Price Range

15.5616.68

52W Range

8.0124.34

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
13.81%
1 Month
14.51%
3 Months
51.36%
6 Months
22.25%
1 Year
85.77%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FHTX16.650.65504.10
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
-
-2 096.30
-2 030.30
-
-
RevenueValueIndustryS&P 500US Markets
4.67M
0.11
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.40-0.65-62.50
Q04 2021-0.74-0.77-4.05
Q03 2021-0.66-0.71-7.58
Q02 2021-0.63-0.630.00
Q03 2020-2.12-3.12-47.17
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.53
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume111.86K
Shares Outstanding41.47K
Shares Float23.93M
Trades Count2.16K
Dollar Volume1.83M
Avg. Volume86.97K
Avg. Weekly Volume57.53K
Avg. Monthly Volume64.73K
Avg. Quarterly Volume138.67K

Foghorn Therapeutics Inc. (NASDAQ: FHTX) stock closed at 16.65 per share at the end of the most recent trading day (a 4.1% change compared to the prior day closing price) with a volume of 111.86K shares and market capitalization of 690.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 85 people. Foghorn Therapeutics Inc. CEO is Adrian Gottschalk.

The one-year performance of Foghorn Therapeutics Inc. stock is 85.77%, while year-to-date (YTD) performance is -27.2%. FHTX stock has a five-year performance of %. Its 52-week range is between 8.01 and 24.34, which gives FHTX stock a 52-week price range ratio of 52.91%

Foghorn Therapeutics Inc. currently has a PE ratio of -5.60, a price-to-book (PB) ratio of 8.79, a price-to-sale (PS) ratio of 130.33, a price to cashflow ratio of 2.40, a PEG ratio of 2.32, a ROA of -29.31%, a ROC of -63.37% and a ROE of -106.55%. The company’s profit margin is -%, its EBITDA margin is -2 030.30%, and its revenue ttm is $4.67 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Foghorn Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.53 for the next earnings report. Foghorn Therapeutics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Foghorn Therapeutics Inc. is Strong Buy (1.1), with a target price of $24, which is +44.14% compared to the current price. The earnings rating for Foghorn Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Foghorn Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Foghorn Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.45, ATR14 : 1.10, CCI20 : 234.77, Chaikin Money Flow : 0.04, MACD : 0.46, Money Flow Index : 75.87, ROC : 8.19, RSI : 48.66, STOCH (14,3) : 98.97, STOCH RSI : 1.00, UO : 55.08, Williams %R : -1.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Foghorn Therapeutics Inc. in the last 12-months were: Adrian Gottschalk (Option Excercise at a value of $12 420), Allan Reine (Option Excercise at a value of $100 038), Carl P. Decicco (Option Excercise at a value of $388 033), Steven F. Bellon (Option Excercise at a value of $14 320)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
3 (75.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.10
Strong Buy
1.13

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

CEO: Adrian Gottschalk

Telephone: +1 617 586-3100

Address: 100 Binney Street, Cambridge 02142, MA, US

Number of employees: 85

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

55%45%

Bearish Bullish

42%58%

TipRanks News for FHTX

Tue, 10 May 2022 10:37 GMT Foghorn Therapeutics (FHTX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits